Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Richtig, E; Langmann, G; Schlemmer, G; Müllner, K; Papaefthymiou, G; Bergthaler, P; Smolle, J.
Safety and efficacy of interferon alfa-2b in the adjuvant treatment of uveal melanoma
OPHTHALMOLOGE. 2006; 103(6): 506-511.
Doi: 10.1007/s00347-006-1350-7
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Richtig Erika
- Co-Autor*innen der Med Uni Graz
- Langmann Gerald
- Müllner Katharina
- Papaefthymiou Georgios
- Schlemmer Gregor
- Smolle Josef
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- PURPOSE: In this manuscript, the safety and efficacy of adjuvant interferon alfa 2b treatment of uveal melanoma is described.PATIENTS AND METHODS: A total of 39 patients (23 male and 16 female, mean age 56.5 years, range 35-78 years) with uveal melanoma were treated with interferon alfa 2b, 3 million units three times a week subcutaneously for 1 year after therapy of the primary tumor. In all patients age, gender, primary melanoma data, therapeutic interventions, treatment side effects and outcome were documented.RESULTS: Of the 39 patients, 31 (80%) finished the treatment as scheduled after 1 year. In 18 patients (46%) the initial dose had to be reduced due to leucopenia, thrombopenia, cardiac symptoms, elevated of liver function or vertigo (WHO grade I-III). In eight patients, therapy had to be withdrawn because of serious side effects (five patients) and the appearance of metastases (three patients). Neither a univariate approach nor a multivariate approach could show a protective effect of interferon treatment on survival.CONCLUSIONS: Adjuvant treatment of uveal melanoma with interferon alfa should be abandoned until the question of dose and administration for cutaneous melanoma is solved.
- Find related publications in this database (using NLM MeSH Indexing)
- Adult -
- Aged -
- Antineoplastic Agents - administration and dosage
- Chemotherapy, Adjuvant - administration and dosage
- Female - administration and dosage
- Humans - administration and dosage
- Interferon Alfa-2b - administration and dosage
- Male - administration and dosage
- Melanoma - drug therapy
- Middle Aged - drug therapy
- Risk Assessment - methods
- Risk Factors - methods
- Treatment Outcome - methods
- Uveal Neoplasms - drug therapy
- Find related publications in this database (Keywords)
- uveal melanoma
- adjuvant treatment
- interferon alfa
- safety
- efficacy